Articles from Cabbacis Inc

Cabbacis (OTCQB: CABI), a U.S. federally-licensed tobacco-product manufacturer focused on harm-reduction products being developed under the iBlend™ brand name, released its clinical trial results demonstrating that the Company’s patented iBlend™ cigarettes were highly rated for satisfaction on the standardized mCEQ questionnaire and significantly reduced cravings for usual brand cigarettes.

Cabbacis (OTCQB: CABI), a U.S. federally-licensed tobacco-product manufacturer focused on harm-reduction products being developed under the iBlend™ brand name, announced that it has filed its Annual Report yesterday on Form 1-K for the fiscal year ended December 31, 2024 with the U.S. Securities and Exchange Commission (the “SEC”).

Cabbacis (OTCQB: CABI), a U.S. federally-licensed tobacco product manufacturer and plant biotech company focused on tobacco harm-reduction products, is pleased to announce that its common stock has been approved for listing on the OTCQB. The stock will trade under the symbol CABI.

Cabbacis (the “Company”), a U.S. federally-licensed tobacco product manufacturer and plant biotech company focused on harm reduction products, announced today that it has filed its Semiannual Report on Form 1-SA for the six-month period ending June 30, 2024 with the U.S. Securities and Exchange Commission (the “SEC”).

Cabbacis (the “Company”), a U.S. federally-licensed tobacco product manufacturer and plant biotech company focused on harm reduction products, announced today that it has licensed a flue-cured, low-nicotine tobacco line from North Carolina State University (NCSU).

Cabbacis (the “Company”), a U.S. federally-licensed tobacco product manufacturer and plant biotech company focused on harm reduction products, announced today that it has filed its Annual Report on Form 1-K for the fiscal year ended December 31, 2023 with the U.S. Securities and Exchange Commission (the “SEC”).

Cabbacis Inc (“Cabbacis” or the “Company”), a U.S. federally-licensed tobacco product manufacturer and plant biotech company focused on harm reduction products, announced today that investors can now participate in the Company’s Regulation A (Tier 2) initial public offering (IPO) through a capital raising portal.